- https://doi.org/10.12765/cpos-2025-08
50 Years of Communicating Demographic and Population Research in Germany
Translate Article 
Take Notes In his editorial, former CPoS editor Johannes Huinink reflects on his personal experiences with the journal as author, advisory board member and editor. He emphasizes the importance of scholarly debates, efforts to include contributions from the Global South, and shares his perspectives for the journal’s continued development and success. He focuses on both the ZfB and CPoS years. The ZfB played a key role in re-establishing demography as a scientific discipline in Germany. Since its relaunch in 2010 as CPoS, the journal has become an internationally recognized, English-language open-access platform with a strong focus on thematic Special Issues. * This article belongs to a series celebrating the journal's 50th anniversary.
- Abstract
1 - 10.1182/blood.v126.23.3511.3511
- Dec 3, 2015
- Blood
Genotype Analysis of Patients with Hereditary Factor X Deficiency Enrolled in 2 Phase 3 Studies of Pdfx, a New High-Purity Factor X Concentrate
- Abstract
- 10.1182/blood-2018-99-117289
- Nov 29, 2018
- Blood
Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials
- Abstract
- 3
- 10.1182/blood-2018-99-112179
- Nov 29, 2018
- Blood
Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study
- Abstract
- 3
- 10.1182/blood-2018-99-112174
- Nov 29, 2018
- Blood
Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
- Abstract
- 2
- 10.1182/blood-2018-99-112125
- Nov 29, 2018
- Blood
Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
- Abstract
- 3
- 10.1182/blood-2018-99-112177
- Nov 29, 2018
- Blood
Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study
- Abstract
- 10.1182/blood.v122.21.5401.5401
- Nov 15, 2013
- Blood
Lenalidomide Is Effective Treating Patients With Relapsed Multiple Myeloma and Very Severe Renal Impairment
- Abstract
- 101
- 10.1093/annonc/mdy424.045
- Oct 1, 2018
- Annals of Oncology
LBA8_PR - KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
- Abstract
- 13
- 10.1182/blood.v126.23.551.551
- Dec 3, 2015
- Blood
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B
- Research Article
- 10.1002/ejic.201801458
- Jan 3, 2019
- European Journal of Inorganic Chemistry
Endings and New Beginnings
- Research Article
- 10.1002/ejoc.202201429
- Jan 2, 2023
- European Journal of Organic Chemistry
Happy 25th Anniversary, EurJOC!
- Abstract
- 11
- 10.1182/blood.v120.21.905.905
- Nov 16, 2012
- Blood
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study
- Abstract
- 15
- 10.1182/blood-2021-147897
- Nov 5, 2021
- Blood
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
- Abstract
- 2
- 10.1182/blood-2021-149433
- Nov 5, 2021
- Blood
Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort
- Abstract
- 10.1182/blood-2021-148481
- Nov 5, 2021
- Blood
Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
